A new oral formulation for the release of sodium butyrate in the ileo-cecal region and colon

Math 1 Math(A1).

Figure 1 Excretion of breath ¹³CO₂ after oral administration of uncoated (A) and shellac-coated (B) 1 g NaB tablets containing 10% w/w of ¹³C-NaB in 12 healthy subjects. The experiment of each formulation was repeated three times in the same subject for different weeks.

Figure 2 Profiles of the mean ¹³CO₂ breath excretion (▲) and serum TUDCA concentrations (■) plotted against time. Data were collected after administration of the Shellac-coated tablet containing 10% w/w of ¹³C-butyrate and two gelatine capsules containing 250 mg each of TUDCA. Data are expressed as mean ± SD in 12 healthy subjects (A) and 12 Crohn’s disease patients (B).

Figure 3 Tmax obtained in control subjects (A) and Crohn’s disease patients (B) using serum TUDCA and ¹³CO₂ breath tests.